| scholarly article | Q13442814 |
| P50 | author | Herbert Loong | Q60487169 |
| P2093 | author name string | Elizabeth Fox | |
| Thomas John | |||
| Benjamin Besse | |||
| Luis Paz-Ares | |||
| Sant P Chawla | |||
| Ignacio Garrido-Laguna | |||
| George D Demetri | |||
| Marwan Fakih | |||
| Young Kwang Chae | |||
| Pilar Garrido | |||
| Na Cui | |||
| John C Krauss | |||
| Anna F Farago | |||
| Alexander Drilon | |||
| Timothy R Wilson | |||
| Jorge Nieva | |||
| Alice T Shaw | |||
| Robert C Doebele | |||
| Ann Johnson | |||
| Byung Chul Cho | |||
| Daniel W Bowles | |||
| Takashi Seto | |||
| Todd Riehl | |||
| Brian Simmons | |||
| Stephen V Liu | |||
| Salvatore Siena | |||
| Minal Barve | |||
| Collin M Blakely | |||
| Lyudmila Bazhenova | |||
| Conor Steuer | |||
| Edna Chow-Maneval | |||
| Diego Tosi | |||
| Gary L Buchschacher | |||
| Darren Sigal | |||
| Paul Conkling | |||
| Susan Eng | |||
| Tobias R Overbeck | |||
| trial investigators | |||
| P2860 | cites work | The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition | Q27681998 |
| Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor | Q27704291 | ||
| Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. | Q27852601 | ||
| NTRK gene fusions as novel targets of cancer therapy across multiple tumour types | Q28066821 | ||
| TRKing down an old oncogene in a new era of targeted therapy | Q28254287 | ||
| An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101 | Q28265615 | ||
| Oncogenes in solid human tumours | Q28279392 | ||
| A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences | Q28282360 | ||
| Late recurrence in pediatric cancer: a report from the Childhood Cancer Survivor Study | Q33567577 | ||
| Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer | Q34501536 | ||
| Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer | Q34501607 | ||
| Targeting TRK family proteins in cancer | Q34550777 | ||
| Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. | Q37357286 | ||
| Entrectinib: a potent new TRK, ROS1, and ALK inhibitor | Q38604854 | ||
| Systemic Treatments in Soft Tissue Sarcomas | Q38759426 | ||
| Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. | Q38821392 | ||
| Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). | Q41636361 | ||
| Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. | Q52692152 | ||
| TRKA expression and NTRK1 gene copy number across solid tumours. | Q54978172 | ||
| Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma | Q62820070 | ||
| Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study | Q88239560 | ||
| Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors | Q90528991 | ||
| Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations | Q90858855 | ||
| Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics | Q91020864 | ||
| Molecular characterization of cancers with NTRK gene fusions | Q91254448 | ||
| P433 | issue | 2 | |
| P921 | main subject | phase I clinical trial | Q5452194 |
| P304 | page(s) | 271-282 | |
| P577 | publication date | 2019-12-11 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials | |
| P478 | volume | 21 |
| Q91793281 | An annual review of the remarkable advances in lung cancer clinical research in 2019 |
| Q98829676 | Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions |
| Q96128110 | Chromosomal translocation-derived aberrant Rab22a drives metastasis of osteosarcoma |
| Q95840207 | Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC) |
| Q100731915 | Cytomorphologic features of NTRK-rearranged thyroid carcinoma |
| Q96341728 | Developing drugs for tissue agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine |
| Q103836731 | Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance |
| Q100533696 | Gap between pediatric and adult approvals of molecular targeted drugs |
| Q96302702 | Histology-agnostic drug development - considering issues beyond the tissue |
| Q92891966 | Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion |
| Q100525979 | Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma |
| Q89916769 | NTRK gene fusions: a rough diamond ready to sparkle |
| Q90308323 | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma |
| Q94465302 | Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group |
| Q100465187 | Problematic breast tumors reassessed in light of novel molecular data |
| Q95289258 | Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment |
| Q104289124 | Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer |
Search more.